Insiders · SNOA

John Mclaughlin

Director at Sonoma Pharmaceuticals, Inc. (SNOA)

John Mclaughlin has filed 5 insider reports with the SEC since January 2022, as director at Sonoma Pharmaceuticals, Inc. (SNOA). The latest filing, on July 10, 2026, reports grant or award at Sonoma Pharmaceuticals, Inc. (SNOA).

Filings
5
Companies
1
Bought on market
None
Sold on market
None

Companies where John Mclaughlin is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Sonoma Pharmaceuticals, Inc. logo
SNOA
Sonoma Pharmaceuticals, Inc.
Director$0.8802Jul 10, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare John Mclaughlin with

Other insiders at the same companies

Questions about John Mclaughlin

What is John Mclaughlin's role at Sonoma Pharmaceuticals, Inc.?
John Mclaughlin reports to the SEC as director at Sonoma Pharmaceuticals, Inc. (SNOA), according to the latest filing on July 10, 2026.
Has John Mclaughlin bought or sold stock recently?
No open-market purchases or sales by John Mclaughlin are on file. The filings report grant or award.
How do I get alerts when John Mclaughlin files?
Follow John Mclaughlin on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by John Mclaughlin (SEC CIK 0001203240). Totals count each trade once, skipping amendments whose original is on file, from Jan 15, 2022 on. View on SEC EDGAR